deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03456817

HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis (ATG2017)

A Phase 2, Open-label Study to Evaluate Graft-vs-host Disease Prophylaxis With High Dose Thymoglobulin, Methotrexate, and Low-dose Cyclosporine in Comparison to Historical/Concurrent Controls Who Received Low Dose Thymoglobulin, Methotrexate, and High-dose Cyclosporine

Sponsor: AHS Cancer Control Alberta

Conditions Graft-versus-host-disease Relapse
Interventions Control Arm - standard of care Treatment Arm - high dose ATG
Updated 14 times since 2018 Last updated: Jul 16, 2025 Started: Jul 1, 2020 Primary completion: May 31, 2025 Completion: May 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow patient accrual and appearance of a toxicity

Other terminated trials from AHS Cancer Control Alberta

See all terminations from AHS Cancer Control Alberta

A PHASE2 clinical study on Graft-versus-host-disease and Relapse, this trial is terminated or withdrawn. The trial is conducted by AHS Cancer Control Alberta and has accumulated 14 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Nov 2022 · 12 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Aug 2025 · 9 months · monthly snapshot~Aug 2025 – present · 11 months · monthly snapshot

Change History

14 versions recorded

  1. Aug 2025 — Present [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Nov 2024 — Aug 2025 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 9 earlier versions

  1. Apr 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  2. Nov 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

  3. Nov 2021 — Nov 2022 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  5. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

  7. Jul 2018 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

  8. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AHS Cancer Control Alberta
Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations